Oxford Science Enterprises
Oxford Science Enterprises is an independent venture capital and venture-building firm founded in 2015 in partnership with the University of Oxford. It finds, funds, and builds companies from Oxford science across Deep Tech, Life Sciences, and HealthTech, with 50+ portfolio companies and £1.3B NAV.
- Company typePrivate
- Founded2015
- HeadquartersOxford, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Oxford Science Enterprises does
Oxford Science Enterprises (OSE) is an independent investment company and venture builder founded in 2015 in Oxford, United Kingdom, in formal partnership with the University of Oxford. The firm operates a "Find-Fund-Build" model that identifies breakthrough research from Oxford, Harwell, and Culham, provides long-duration patient capital, and co-creates spinout companies alongside academic founders and an in-house Entrepreneurs-in-Residence programme. Its 60+ person team is organized across three sector verticals — Deep Tech, Life Sciences, and HealthTech — and supports portfolio companies with operational assistance, board-level governance, recruiting, and access to a global co-investor network.
OSE's portfolio spans 50+ flagship companies including quantum computing firms (Oxford Ionics, Oxford Quantum Circuits, Quantum Motion), biotechs (Dark Blue Therapeutics, Beacon Therapeutics, Alethio Therapeutics, Scripta Therapeutics), HealthTech platforms (Ultromics, Kneu Health/Neu Health), agricultural technology (Wild Bioscience), AI chip developers (Fractile), and aerospace/defence ventures (Applied Atomics). The firm has deployed £3 billion+ alongside 300+ co-investors, holds £1.3 billion in net asset value, and has raised over £850 million from global institutional investors including sovereign wealth funds, family offices, pension funds, and asset managers.
The business model is structured as a venture capital platform: OSE generates revenue through management fees on its £850M+ of raised capital and £1.3B NAV, plus carried interest crystallized on successful portfolio exits. The firm is FCA-authorized through its wholly-owned subsidiary OSE Manager Limited, operates as a public limited company (Oxford Science Enterprises plc), and facilitates secondary trading of its shares via the London Stock Exchange's PISCES platform. Notable recent exits include Oxford Ionics' $1.075 billion acquisition by IonQ (June 2025) and Dark Blue Therapeutics' acquisition by Amgen for up to $840 million (January 2026), alongside active partnerships with The Crown Estate, Pioneer Group, Ellison Institute of Technology, Cedars-Sinai, and Tokyu Land to expand geographic reach and physical infrastructure.
Oxford Science Enterprises firmographics
Firmographics- Name
- Oxford Science Enterprises
- Legal name
- Oxford Science Enterprises plc
- Website
- https://oxfordscienceenterprises.com/
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Oxford Science Enterprises is an independent venture capital and venture-building firm founded in 2015 in partnership with the University of Oxford. It finds, funds, and builds companies from Oxford science across Deep Tech, Life Sciences, and HealthTech, with 50+ portfolio companies and £1.3B NAV.
- Ownership category
- akta.pro rank
Oxford Science Enterprises industry classification
Industry- Product category
- Venture Capital
- NAICS
- Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Emerging Manager / Seeding Platforms (Multi-Manager) (FSANAGAF)
- akta.pro secondary industry
- Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)
Keywords
Where Oxford Science Enterprises is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Oxford Science Enterprises business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Investment Management: OSE operates as an independent investment company that generates returns through capital appreciation of its portfolio companies. Revenue is derived from management fees on funds under management and carried interest on successful exits.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Oxford Science Enterprises product offering
Product offeringCore offering
Oxford Science Enterprises is an independent investment company and venture builder that finds, funds, and builds companies based on University of Oxford science across Deep Tech, Life Sciences, and HealthTech. It deploys patient capital across pre-seed to growth stages, co-creates ventures with researchers and Entrepreneurs-in-Residence, and provides operational support including strategy, recruitment, business development, and access to lab/startup space. The firm partners with global specialist investors to co-invest and scale Oxford spinouts from lab breakthrough to commercial company.
Product overview
Oxford Science Enterprises is an independent investment company and venture builder powered by a unique partnership with the University of Oxford. Rather than offering a single unified product, the company operates a venture-building engine that systematically creates and scales spinout companies across three sectors: Deep Tech, Life Sciences, and HealthTech. Their model involves identifying bold ideas from Oxford researchers, funding them with patient capital, and building companies ready to change the world. The portfolio includes quantum computing companies (Oxford Ionics, Oxford Quantum Circuits), biotech firms (Dark Blue Therapeutics, Beacon Therapeutics, Alethio Therapeutics), agricultural technology (Wild Bioscience), medical AI diagnostics (Ultromics, Kneu Health), and numerous other specialized ventures. As of 2026, the firm has built 50+ flagship companies, attracted 300+ co-investors, and manages £1.3 billion in net asset value.
Differentiator
Problem solved
Functional benefit
Products and services
- Venture Building and Investment Services An integrated venture capital and venture-building service that finds, funds, and builds transformational companies from University of Oxford science across Deep Tech, Life Sciences, and HealthTech. Delivered to (a) Oxford researchers and innovators seeking to commercialise breakthroughs, and (b) global investors seeking exposure to Oxford spinouts through co-investment and OSE plc equity. Includes pre-seed to growth-stage equity investment, patient capital, Entrepreneurs-in-Residence, recruitment, strategy, business development, and 55,000+ sq ft of laboratory and startup space.
Quantifiable outcome
- Created 50+ flagship companies from Oxford science since 2015
- +3 more outcomes
Companies that use Oxford Science Enterprises
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Oxford Science Enterprises technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Oxford Science Enterprises partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- The Crown EstatecorePartnership to convert former Debenhams building at 1-12 Magdalen Street in Oxford into a 100,000 sq ft laboratory and innovation hub for life sciences, technology and research businesses. The £125m development is scheduled for 2027-2029.
- Pioneer GroupcoreScience and innovation developer partnering with OSE and The Crown Estate to develop the 100,000 sq ft laboratory and innovation hub in Oxford.
- Archangel Lightworks (Omantel partnership facilitated by OSE)minorOSE facilitated partnership between Archangel Lightworks and Omantel to introduce laser-optic satellite ground station communication technologies in Oman, including proof-of-concept trials and joint R&D.
- UK Government / Chancellor Reeves Gulf MissionminorOSE participated in UK Chancellor's Gulf trade mission alongside Darktrace and Oxford Nanopore Technologies to promote UK investment opportunities.
- Tokyu LandminorPartnership to connect Oxford spinouts with Japan's innovation ecosystem, helping portfolio companies access the Japanese market and potential partners/investors.
- Cedars-SinaicoreStrategic partnership and co-investment in neurology care company Kneu Health (now Neu Health), with Cedars-Sinai adopting the platform and investing to accelerate U.S. market entry.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Oxford Science Enterprises competitors and assessment
Company assessmentDirect peers
- Cambridge Innovation Capital: CIC is the closest analogue to OSE: a Cambridge University-partnered venture builder that invests in deep tech and life sciences spinouts from a single elite research university. The model, university anchor, sector mix, and UK base make it the most directly comparable peer.
- Apollo Therapeutics: A venture builder partnering with multiple UK universities (Cambridge, UCL, Imperial) to translate academic research into biotech companies. Comparable in university-partnered venture building and life-sciences focus, with a multi-institution twist that contrasts with OSE's single-university anchor.
- IP Group: UK-listed IP commercialization firm that partners with multiple universities to form and back spinouts across life sciences, deep tech, and cleantech. Closely comparable in commercialization model and sector mix, though it works with a portfolio of universities rather than a single anchor.
Broad incumbents
- Oxford University Innovation: Oxford's official technology transfer office and OSE's primary partner. Comparable in mission (commercializing Oxford IP) and customer base, but operates as the university's in-house tech-transfer function rather than a venture-building investor, making it more of an upstream enabler than a direct competitor.
- Flagship Pioneering: US-based venture creation firm that originates and builds biotech and life-sciences companies. Comparable in 'venture builder' DNA and life-sciences focus, but operates at much larger scale, is private, and does not anchor to a single university.
- Wellcome Leap: US-based program of the Wellcome Trust funding breakthrough life-sciences and health research. Comparable in life-sciences/health focus and willingness to back early-stage, capital-intensive science, but operates as a philanthropic program rather than a return-driven VC.
- SVB Capital / Silicon Valley Bank Ventures: Long-standing US investor in university spinouts and life-sciences/deep-tech companies. Comparable in supporting deep tech and life-sciences venture creation, with a more diversified LP-funded model rather than a single-university anchor.
- Mubadala Capital Ventures: Sovereign-backed investor with global venture activity including deep tech and life sciences. Comparable in deploying very large pools of patient capital into long-horizon science, though diversified across sectors and geographies rather than university-anchored.
Emerging players
- The Engine (MIT): MIT-affiliated venture fund focused on 'tough tech' (deep tech, advanced materials, energy, biotech). Comparable as a university-anchored deep-tech investor and venture builder, though smaller in scale and US-based rather than UK-based.
Regional players
- Parkwalk Advisors: UK-based investor focused on university spinouts, particularly from the 'golden triangle' of Oxford, Cambridge, and Imperial. Comparable in UK university spinout focus and EIS-eligible structure, though smaller in scale and multi-university rather than single-anchored.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Oxford Science Enterprises social profiles
Digital presenceOxford Science Enterprises compliance and trust
Trust signalCompliance3 records
Oxford Science Enterprises financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oxford Science Enterprises leadership team
Management profileNumber of profiles
Profiles12 records
Oxford Science Enterprises subsidiaries and ownership
Company hierarchySubsidiaries1 record
Oxford Science Enterprises funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oxford Science Enterprises M&A and investment
M&A and investmentM&A
Investments190 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oxford Science Enterprises
What does Oxford Science Enterprises do?
Oxford Science Enterprises is an independent investment company and venture builder that finds, funds, and builds companies based on University of Oxford science across Deep Tech, Life Sciences, and HealthTech. It deploys patient capital across pre-seed to growth stages, co-creates ventures with researchers and Entrepreneurs-in-Residence, and provides operational support including strategy, recruitment, business development, and access to lab/startup space. The firm partners with global specialist investors to co-invest and scale Oxford spinouts from lab breakthrough to commercial company.
Is Oxford Science Enterprises a public or private company?
Oxford Science Enterprises is a private company. It is classified as venture growth investor backed and is currently operating.
When was Oxford Science Enterprises founded?
Oxford Science Enterprises was founded in 2015. It employs 51 to 100 people.
Where is Oxford Science Enterprises based?
Oxford Science Enterprises is headquartered in Oxford, United Kingdom, in the Europe region.
How does Oxford Science Enterprises make money?
One revenue line is on record: investment Management.
Who are Oxford Science Enterprises's main competitors?
Direct peers on record are Cambridge Innovation Capital, Apollo Therapeutics and IP Group. Broad incumbents are Oxford University Innovation, Flagship Pioneering, Wellcome Leap, SVB Capital / Silicon Valley Bank Ventures and Mubadala Capital Ventures. The Engine (MIT) is listed as an emerging player. Parkwalk Advisors is listed as a regional player.
Does Oxford Science Enterprises have an API?
No public API is recorded for Oxford Science Enterprises.
What industry is Oxford Science Enterprises in?
Oxford Science Enterprises's product category is Venture Capital. Its primary akta.pro industry code is FSANAGAF, Emerging Manager / Seeding Platforms (Multi-Manager), with a secondary code of EDAHABAH, Technology Transfer & Innovation-Driven Research Universities (High Commercialization). Its NAICS code is 52394 and its SIC code is 6282.